Applicants should hold a PhD and/or MD, and have postdoctoral research experience in the area of hematology/oncology research, specifically on the differentiation of acute myelogenous leukemia (AML), genes involved in AML relapse, inflammation in AML, and detection of minimal residual disease (MRD). Applicants' research should also focus on how sterile inflammation and interferon signaling disrupt TP53-mediated apoptosis in AML, driving therapy resistance, and informing new strategies to overcome it. Evidence of scholarly ability (i.e., record of publications in peer-reviewed journals, acquisition of external funding, and presentation experience) is expected.